COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival | MicrobiomeTrials← Back to trialsNCT07729241
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
RecruitingOBSERVATIONAL
Trial Details
Start: 2020-12-28Est. Completion: 2024-12-31
Enrollment target: 95,015 participants Locations- Hôpital Pitié Salpêtrière / CIC-2503, Paris, Paris, France
Other microbiome trials you might be interested in
Very Rare TumorsVery Rare CancersOther Solid TumorsSolid TumorPediatric Rare Tumors
Background:
All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewe…
Bethesda, United StatesEst. completion Apr 1, 2035
Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial Carcinoma
Muscle Invasive Urethral Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or uret…
Phoenix, United StatesEst. completion Sep 2, 2030
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029